Speaker illustration

Doctor Filipe Moura

Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)

Member of:

European Society of Cardiology

Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: A patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials

Event: ESC Congress 2022

Topic: Diabetes and the Heart

Session: Obesity and diabetes: key role for risk factor management

Thumbnail

This platform is supported by

logo Novo Nordisk